Real‐World Effectiveness of Rebamipide on Gastritis Symptoms: A Patient‐Focused Approach
Clinical and Translational Science · 2025-09 · 18 (9)
DOI: 10.1111/cts.70327 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical and Translational Science, online erschienen am 23.08.2025. Verfasst von Hyun Ji Woo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Healthcare Engineering, Graduate School, Jeonbuk National University, Jeonju, Republic of Korea. Hauptthemen laut MEDLINE: Alanine, Quinolones, Gastritis, Anti-Ulcer Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Daewoong Pharmaceutical Co. Ltd., Korea Health Industry Development Institute, Ministry of Health & Welfare, Republic of Korea.
Abstract (Originalsprache)
Rebamipide is a gastric mucosal protectant used to relieve gastritis symptoms. Real‐world evidence on the comparative effectiveness of rebamipide monotherapy versus combination therapy with proton‐pump inhibitors (PPIs) in routine clinical settings is limited. This study evaluated the effect of rebamipide in reducing subjective gastrointestinal (GI) symptoms among patients with gastritis symptoms using a patient‐focused approach. This multicenter, observational study enrolled patients aged 19 years and older who were prescribed rebamipide for gastritis symptoms across 81 local clinics and hospitals. Patients received rebamipide twice daily for 2 weeks, with an optional 4‐week extension. GI symptom severity and frequency were collected via patient‐reported outcomes at baseline and posttreatment. Patients were categorized into a rebamipide monotherapy group and a combination therapy group, with inverse probability of treatment weighting (IPTW) applied to adjust for baseline confounding. Statistical analyses included ANCOVA for symptom score changes and chi‐square tests for categorical symptom improvement. Of the 2209 patients included in the analysis, 1946 were in the monotherapy and 263 were in the combination therapy. Both treatment groups showed significant posttreatment reductions in GI symptom scores, and there was no significant difference between the two groups in severity, frequency, and total score before and after IPTW ( p > 0.05). The symptom improvement rate (≥ 50% reduction) was 71.5% in the monotherapy group and 71.4% in the combination therapy group, with no significant difference between the two groups ( p = 0.976). Rebamipide monotherapy provided similar levels of GI symptom relief compared to combination therapy with PPIs in a real‐world clinical setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Healthcare Engineering, Graduate School, Jeonbuk National University, Jeonju, Republic of Korea.
- Nanum Space Co. Ltd, Jeonju, Republic of Korea.
- Division of Biomedical Engineering, College of Engineering, Jeonbuk National University, Jeonju, Republic of Korea.
- Research Institute of Clinical Medicine of Jeonbuk National University, Jeonju, Republic of Korea.
- Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Republic of Korea.
- Center for Clinical Pharmacology, Jeonbuk National University Hospital, Jeonju, Republic of Korea.
ORCID-Profile: Hyun Ji Woo, Tae-Kyu Kwon, Seol Ju Moon, Min-Gul Kim
Förderung
- Daewoong Pharmaceutical Co. Ltd.
- Korea Health Industry Development Institute
- Ministry of Health & Welfare, Republic of Korea
Zitieren
APA
Woo, H. J., Kwon, T. K., Moon, S. J., & Kim, M. G. (2025). Real‐World Effectiveness of Rebamipide on Gastritis Symptoms: A Patient‐Focused Approach. Clinical and Translational Science, 18(9). https://doi.org/10.1111/cts.70327
Vancouver
Woo HJ, Kwon TK, Moon SJ, Kim MG. Real‐World Effectiveness of Rebamipide on Gastritis Symptoms: A Patient‐Focused Approach. Clinical and Translational Science. 2025;18(9). doi:10.1111/cts.70327
BibTeX
@article{Woo2025,
author = {Woo, Hyun Ji and Kwon, Tae-Kyu and Moon, Seol Ju and Kim, Min-Gul},
title = {Real‐World Effectiveness of Rebamipide on Gastritis Symptoms: A Patient‐Focused Approach},
journal = {Clinical and Translational Science},
year = {2025},
volume = {18},
number = {9},
doi = {10.1111/cts.70327}
}
EUVIMED